Kivu Bioscience https://validator.w3.org/feed/docs/rss2.html Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates Kivu Bioscience Jennifer Cochran, PhD Michaël Vlemmix Max Klement, PhD Daniel O’Connell, MD, PhD Julie Hambleton, M.D. Bauke Anninga, PhD Mårten Steen, MD, PhD Edward van Wezel Wafa QuliKhan, MBBS Anderson Chang, PhD Tessie Ng, PhD Xiaoyue Jiang, PhD Natasja Viller, PhD Sy-Dang Tran, MBA Minke Binnerts, PhD Liangyi Zhang, PhD Ann MacLaren, PhD Synaffix, industry’s ADC partner of choice, spins out a startup pipeline Gavin Choy, PharmD, MBA Backed by Novo, Kivu debuts with $92M to build ‘kinder, gentler’ medicines With $92M, Kivu sets out to make ‘kinder, gentler’ ADCs Kivu Bioscience Appoints Julie Hambleton, M.D., to its Board of Directors Brunilda Shtylla Kivu Bioscience Appoints Brunilda Shtylla as Chief Business Officer Kivu Bioscience Appoints Sophia Randolph, M.D., Chief Medical Officer Kivu Bioscience Presents Preclinical Data for KIVU-107 Demonstrating Potent and Durable Anti-Tumor Activity and a Wide Therapeutic Index at World ADC San Diego 2025 Contact Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors Sophia Randolph, MD, PhD Mohit Trikha, PhD Kivu Bioscience Selects Sterling Pharma Solutions for cGMP Manufacturing of Lead Oncology Antibody-Drug Conjugate KIVU-107 Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical Trial